References
- Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30: 4558-65. doi: 10.1200/ JCO.2012.42.8771
- Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-87. doi: 10.1016/S1470-2045(12)70187-0
- O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014; 32: 1927-34. doi: 10.1200/ JCO.2013.53.7753
- Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 29-42. doi: 10.1016/S1470-2045(20)30555-6
- Arbea L, Ramos LI, Martínez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol 2010; 5: 17. doi: 10.1186/1748-717X-5-17
- Guerrero Urbano MT, Henrys AJ, Adams EJ, Norman AR, Bedford JL, Harrington KJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys 2006; 65: 907-16. doi: 10.1016/j. ijrobp.2005.12.056
- Engels B, De Ridder M, Tournel K, Sermeus A, De Coninck P, Verellen D, et al. Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel. Int J Radiat Oncol Biol Phys 2009; 74: 1476-80. doi: 10.1016/j.ijrobp.2008.10.017
- Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 2011; 6: 63. doi: 10.1186/1748-717X-6-63
- Li JL, Ji JF, Cai Y, Li XF, Li YH, Wu H, et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial. Radiother Oncol 2012; 102: 4-9. doi: 10.1016/j.radonc.2011.07.030
- Engels B, Platteaux N, Van den Begin R, Gevaert T, Sermeus A, Storme G, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol 2014; 110: 155-9. doi: 10.1016/j. radonc.2013.10.026
- Hernando-Requejo O, López M, Cubillo A, Rodriguez A, Ciervide R, Valero J, et al. Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol 2014; 190: 515-20. doi: 10.1007/s00066-014-0650-0
- Picardi V, Macchia G, Guido A, Giaccherini L, Deodato F, Farioli A, et al. Preoperative chemoradiation with VMAT-SIB in rectal cancer: a phase II study. Clin Colorectal Cancer 2017; 16: 16-22. doi: 10.1016/j. clcc.2016.06.004
- Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15: 1245-53. doi: 10.1016/S1470-2045(14)70377-8
- Zhu J, Liu F, Gu W, Lian P, Sheng W, Xu J, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol 2014; 9: 70. doi: 10.1186/1748-717X-9-70
- Hong TS, Moughan J, Garofalo MC, Bendell J, Berger AC, Oldenburg NB, et al. NRG Oncology Radiation Therapy Oncology Group 0822: a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015; 93: 29-36. doi: 10.1016/j.ijrobp.2015.05.005
- But-Hadzic J, Anderluh F, Brecelj E, Edhemovic I, Secerov-Ermenc A, Hudej R, et al. Acute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated boost: a phase 2 trial. Int J Radiat Oncol 2016; 96: 1003-10. doi: 10.1016/j.ijrobp.2016.08.031
- But-Hadzic J, Velenik V. Preoperative intensity-modulated chemoradiation therapy with simultaneous integrated boost in rectal cancer: 2-year follow-up results of phase II study. Radiol Oncol 2018; 52: 23-29. doi: 10.1515/ raon-2018-0007
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4. doi: 10.1245/s10434-010-0985-4
- Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23. doi: 10.1007/s003840050072
- Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) v5.0.; 2017. [cited 2021 Feb 04]. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76. doi: 10.1093/jnci/85.5.365
- van der Hout A, Neijenhuijs KI, Jansen F, van Uden-Kraan CF, Aaronson NK, Groenvold M, et al. Measuring health-related quality of life in colorectal cancer patients: systematic review of measurement properties of the EORTC QLQ-CR29. Support Care Cancer 2019; 27: 2395-412. doi: 10.1007/ s00520-019-04764-7
- Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. European Organisation for Research and Treatment of Cancer; 2001. [cited 2021 Feb 04]. Available at https://abdn.pure.elsevier.com/en/publications/eortc-qlq-c30-scoring-manual-3rd-edition
- Hanna CR, Slevin F, Appelt A, Beavon M, Adams R, Arthur C, et al. Intensity-modulated radiotherapy for rectal cancer in the UK in 2020. Clin Oncol 2021; 33: 214-23. doi: 10.1016/j.clon.2020.12.011
- Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28: 859-65. doi: 10.1200/JCO.2009.25.8541
- Tey J, Leong CN, Cheong WK, Sze TG, Yong WP, Tham IWK, et al. A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer. J Cancer 2017; 8: 3114-21. doi: 10.7150/jca.21237
- Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a radio-sensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J 2006; 47: 693-700.
- Simson DK, Mitra S, Ahlawat P, Saxena U, Sharma MK, Rawat S, et al. Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer – Toxicities and response assessment. Cancer Manag Res 2018; 10: 519-26. doi: 10.2147/CMAR.S142076
- Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 2010; 5: 88. doi: 10.1186/1748-717X-5-88
- Garofalo M, Moughan J, Hong T, J.Bendell, A.Berger, F.Lerma, et al. RTOG 0822: a phase II study of preoperative (PREOP) chemoradiotherapy (CRT) utilizing IMRT in combination with capecitabine (C) and oxaliplatin (O) for patients with locally advanced rectal cancer. Int J Radiat Oncol 2011; 81: S3-S4. doi: 10.1016/j.ijrobp.2011.06.008
- Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014; 32: 1554-62. doi: 10.1200/JCO.2013.54.3769
- George TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a new surrogate endpoint in rectal cancer clinical trials. Curr Colorectal Cancer Rep 2015; 11: 275-80. doi: 10.1007/s11888-015-0285-2
- Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-44. doi: 10.1016/S1470-2045(10)70172-8
- Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40. doi: 10.1056/NEJMoa040694
- Urso E, Serpentini S, Pucciarelli S, De Salvo GL, Friso ML, Fabris G, et al. Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. Eur J Surg Oncol 2006; 32: 1201-8. doi: 10.1016/j.ejso.2006.07.003
- Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-23. doi: 10.1056/NEJMoa060829
- Velenik V, Secerov-Ermenc A, But-Hadzic J, Zadnik V. Health-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general slovenian population. Radiol Oncol 2017; 51: 342-50. doi: 10.1515/ raon-2017-0021
- Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. EORTC Quality of Life Group. EORTC QLQ-C30 Reference Values; 2008. [cited 2021 Feb 04]. Available at https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf